GLP-1 receptor agonists semaglutide and tirzepatide are associated with reduced risks of dementia, stroke, and mortality in adults with type 2 diabetes and obesity, new data show.

A new study has found that a drug used for treating obesity and type 2 diabetes may also help slow the growth of breast cancer caused by obesity.

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

The researchers estimate 6.5 billion years of life will likely be lost globally due to premature deaths caused by obesity’s negative health effects. The weight loss drugs could lead to a disruptive ...

A new study has found that an anti-obesity drug called tirzepatide, which is sold under the names Mounjaro for diabetes and ...

Pennington Biomedical researchers and their collaborators observed decreased activity in the brain regions responsible for ...

Wegovy, India’s first injectable semaglutide for chronic weight management, recorded Rs 2.54 crore in sales in June ...

Presented by AstraZeneca{beacon} Health Care Health Care   The Big Story CMS targets hospitals with site-neutral drug ruleThe ...

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.

For people who are obese and have type 2 diabetes, using Ozempic and other GLP-1 agonist drugs cuts the all-cause mortality rate by 30%, according to a new Use of GLP-1 agonists also cut the risk that ...

Research from ENDO 2025 reveals that GLP-1 anti-obesity medications not only aid in weight loss but also improve testosterone ...